Loading...
•
Dec 31, 2019
CRISPR Therapeutics Q4 2019 Earnings Report
CRISPR Therapeutics reported financial results, highlighting revenue growth and clinical trial advancements.
Key Takeaways
CRISPR Therapeutics reported a net income of $30.5 million for the fourth quarter of 2019, a significant improvement compared to a net loss of $47.6 million for the same period in 2018. Total collaboration revenue was $77.0 million, driven by collaboration agreements with Vertex. The company's cash and cash equivalents reached $943.8 million.
Reported positive interim data from CTX001 clinical trials for beta thalassemia and sickle cell disease.
Continued enrollment in CTX110 clinical trial targeting CD19+ malignancies.
Began enrollment in CTX120 clinical trial targeting BCMA for multiple myeloma.
Announced Q4 2019 collaboration revenue of $77.0 million, driven by Vertex agreements.
Forward Guidance
CRISPR Therapeutics anticipates conducting clinical trials in five indications and expects new data from its immuno-oncology and hemoglobinopathies programs in 2020.
Positive Outlook
- Continued enrollment in clinical trials of CTX001 for severe hemoglobinopathies.
- Ongoing clinical trial of CTX110 targeting CD19+ malignancies.
- Started enrollment in clinical trial of CTX120 targeting BCMA.
- Advancing additional allogeneic CAR-T candidates toward clinical development, including CTX130.
- Expects new data from immuno-oncology and hemoglobinopathies programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...